First Time Loading...

Sonoma Pharmaceuticals Inc
NASDAQ:SNOA

Watchlist Manager
Sonoma Pharmaceuticals Inc Logo
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Watchlist
Price: 0.25 USD 66.67%
Updated: May 17, 2024

Sonoma Pharmaceuticals Inc
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sonoma Pharmaceuticals Inc
Cash & Cash Equivalents Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Cash & Cash Equivalents
$2.4m
CAGR 3-Years
-24%
CAGR 5-Years
-18%
CAGR 10-Years
-4%
Johnson & Johnson
NYSE:JNJ
Cash & Cash Equivalents
$7.2B
CAGR 3-Years
19%
CAGR 5-Years
1%
CAGR 10-Years
-10%
Bristol-Myers Squibb Co
NYSE:BMY
Cash & Cash Equivalents
$9.3B
CAGR 3-Years
-5%
CAGR 5-Years
5%
CAGR 10-Years
6%
Pfizer Inc
NYSE:PFE
Cash & Cash Equivalents
$2.9B
CAGR 3-Years
17%
CAGR 5-Years
8%
CAGR 10-Years
0%
Merck & Co Inc
NYSE:MRK
Cash & Cash Equivalents
$5.6B
CAGR 3-Years
-7%
CAGR 5-Years
-7%
CAGR 10-Years
-10%
Eli Lilly and Co
NYSE:LLY
Cash & Cash Equivalents
$2.5B
CAGR 3-Years
-6%
CAGR 5-Years
4%
CAGR 10-Years
-4%

See Also

What is Sonoma Pharmaceuticals Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
2.4m USD

Based on the financial report for Dec 31, 2023, Sonoma Pharmaceuticals Inc's Cash & Cash Equivalents amounts to 2.4m USD.

What is Sonoma Pharmaceuticals Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-4%

Over the last year, the Cash & Cash Equivalents growth was -9%. The average annual Cash & Cash Equivalents growth rates for Sonoma Pharmaceuticals Inc have been -24% over the past three years , -18% over the past five years , and -4% over the past ten years .